专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2003100033A2 ANTI-αvβ6 ANTIBODIES 审中-公开
标题翻译：抗甲状腺炎抗体
公开(公告)号：WO2003100033A2
公开(公告)日：2003-12-04
申请号：PCT/US2003/008048
申请日：2003-03-13
申请人： BIOGEN, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
发明人： VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
IPC分类号： C12N
CPC分类号： C07K16/2839 , A61K47/48507 , A61K47/48561 , A61K47/48623 , A61K47/68 , A61K47/6835 , A61K47/6849 , A61K47/6851 , A61K47/6865 , A61K51/1027 , A61K51/1066 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92 , G01N33/57492 , G01N33/6893 , G01N2333/70546 , G01N2800/085 , G01N2800/205
摘要： Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having 006-mediated diseases, or to diagnose %Qmediated diseases.
摘要翻译：特异性结合M.96的单克隆抗体。还包括使用这些抗体治疗具有或具有006介导的疾病的风险的哺乳动物或诊断％Q介导的疾病的方法。

2. 发明申请

WO2008008315A2 COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF SMAD4-DEFICIENT CANCERS 审中-公开
标题翻译：抑制SMAD4缺乏癌的生长的组合物和方法
公开(公告)号：WO2008008315A2
公开(公告)日：2008-01-17
申请号：PCT/US2007/015692
申请日：2007-07-10
申请人： BIOGEN IDEC MA INC. , VIOLETTE, Shelia, M. , KOOPMAN, Louise, A.
发明人： VIOLETTE, Shelia, M. , KOOPMAN, Louise, A.
IPC分类号： G01N33/574
CPC分类号： G01N33/5011 , A61K38/1793 , A61K39/39558 , A61K2039/505 , C07K16/2839 , C07K2317/73 , G01N33/5091 , G01N33/574 , G01N33/57407 , A61K2300/00
摘要： The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4 ) and integrin α v β 6 , and the responsiveness of patient populations to α v β 6 -active compounds and compositions (e.g., antibodies and other ligands that bind α v β 6 ), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such α v β 6 -active compounds and compositions by examining the expression of α v β 6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment/prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin α v β 6 on the surfaces of tumor cells and/or that block one or more components of the TGF-β pathway, particularly in 5/≤αrf4-deficient tumor cells.
摘要翻译：本发明涉及细胞生物学，免疫学和肿瘤学领域。本发明涉及在肿瘤抑制基因smad4（也称为dpc4）和整联蛋白的表达水平之间存在关系的发现，以及患者群体对ßß>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> 特别是在来自这些患者群体的癌细胞中，更特别地涉及癌如胰腺癌。因此，本发明提供了通过检查肿瘤细胞（特别是胰腺肿瘤）的表达来确定肿瘤细胞（例如胰腺肿瘤）的反应性的方法，肿瘤细胞中的Smad4和smad4以及使用配体（包括抗体和小分子药物）的诊断和治疗/预防肿瘤进展的方法，所述配体包括抗体和小分子药物，其结合在肿瘤细胞表面上整合整合素和/或阻断TGF-β途径的一种或多种成分，特别是在5 / = arf4缺陷型肿瘤中细胞。

3. 发明申请

WO2003100033A3 ANTI-αvβ6 ANTIBODIES 审中-公开
公开(公告)号：WO2003100033A3
公开(公告)日：2003-12-04
申请号：PCT/US2003/008048
申请日：2003-03-13
申请人： BIOGEN, INC. , THE REGENTS OF THE UNIVERSITY OF CALIFORNIA , VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
发明人： VIOLETTE, Shelia, M. , WEINREB, Paul, H. , SIMON, Kenneth, J. , SHEPPARD, Dean , LEONE, Diane, R.
IPC分类号： A61K39/395
摘要： Monoclonal antibodies that specifically bind to α v β 6 . Also included are methods of using these antibodies to treat mammals having or at risk of having α v β 6 -mediated diseases, or to diagnose α v β 6 -mediated diseases.

4. 发明申请

WO2008008315A3 COMPOSITIONS AND METHODS FOR INHIBITING GROWTH OF SMAD4-DEFICIENT CANCERS 审中-公开
标题翻译：抑制SMAD4缺乏癌的生长的组合物和方法
公开(公告)号：WO2008008315A3
公开(公告)日：2008-12-11
申请号：PCT/US2007015692
申请日：2007-07-10
申请人： BIOGEN IDEC INC , VIOLETTE SHELIA M , KOOPMAN LOUISE A
发明人： VIOLETTE SHELIA M , KOOPMAN LOUISE A
IPC分类号： A61K39/00
CPC分类号： G01N33/5011 , A61K38/1793 , A61K39/39558 , A61K2039/505 , C07K16/2839 , C07K2317/73 , G01N33/5091 , G01N33/574 , G01N33/57407 , A61K2300/00
摘要： The present invention is in the fields of cell biology, immunology and oncology. The invention relates to the discovery that there is a relationship between the expression levels of the tumor suppressor gene smad4 (also known as dpc4) and integrin avß6, and the responsiveness of patient populations to avß6-active compounds and compositions (e.g., antibodies and other ligands that bind avß6), particularly in cancer cells from such patient populations, more particularly on carcinomas such as pancreatic carcinomas. The invention thus provides methods for determining the responsiveness of tumor cells (particularly those from pancreatic tumors) to such avß6-active compounds and compositions by examining the expression of avß6 and smad4 by the tumor cells, as well as methods of diagnosis and treatment/prevention of tumor progression using ligands, including antibodies and small molecule drugs, that bind to integrin avß6 on the surfaces of tumor cells and/or that block one or more components of the TGF-ß pathway, particularly in 5/=arf4-deficient tumor cells.
摘要翻译：本发明涉及细胞生物学，免疫学和肿瘤学领域。本发明涉及以下发现：肿瘤抑制基因smad4（也称为dpc4）和整联蛋白avβ6的表达水平与患者群体对avβ6活性化合物和组合物（例如，抗体和其他物质）的反应性之间存在关系结合avß6）的配体，特别是在来自这样的患者群体的癌细胞中，更特别地涉及癌如胰腺癌。因此，本发明提供了通过检查肿瘤细胞的avß6和smad4的表达以及诊断和治疗/预防的方法来确定肿瘤细胞（特别是来自胰腺肿瘤的细胞）对这种avβ6活性化合物和组合物的反应性的方法使用与肿瘤细胞表面上的整联蛋白avβ6结合的配体（包括抗体和小分子药物）和/或阻断TGF-β途径的一个或多个成分，特别是在5 / arf4缺陷型肿瘤细胞中的配体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式